157 related articles for article (PubMed ID: 16955297)
1. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Di Blasio A; Amiconi G; Lombardo M; Nuzzo A; Lalli A; Alesse E; Necozione S; Rea S
Cancer Immunol Immunother; 2007 May; 56(5):699-708. PubMed ID: 16955297
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.
Recchia F; Saggio G; Nuzzo A; Biondi E; Di Blasio A; Cesta A; Candeloro G; Alesse E; Rea S
J Immunother; 2006; 29(1):87-94. PubMed ID: 16365604
[TBL] [Abstract][Full Text] [Related]
3. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Nuzzo A; Lombardo M; Carta G; Rea S
Int J Oncol; 2005 Oct; 27(4):1039-46. PubMed ID: 16142321
[TBL] [Abstract][Full Text] [Related]
5. Maintenance immunotherapy in metastatic breast cancer.
Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Oncol Rep; 2008 Nov; 20(5):1173-9. PubMed ID: 18949418
[TBL] [Abstract][Full Text] [Related]
6. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
[TBL] [Abstract][Full Text] [Related]
7. Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy.
Recchia F; Cesta A; Rea S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):135-43. PubMed ID: 16767920
[TBL] [Abstract][Full Text] [Related]
8. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.
Masotti A; Morandini G; Ortolani R; Fumagalli L
Lung Cancer; 1998 Jun; 20(3):191-202. PubMed ID: 9733054
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study.
Recchia F; De Filippis S; Rosselli M; Saggio G; Fumagalli L; Rea S
Int J Oncol; 2002 Jun; 20(6):1275-82. PubMed ID: 12012010
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
[TBL] [Abstract][Full Text] [Related]
11. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in patients with less than complete response to chemotherapy.
Recchia F; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Anticancer Res; 2009 Feb; 29(2):567-72. PubMed ID: 19331204
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Recchia F; Saggio G; Candeloro G; Cesta A; Amiconi G; Blasio AD; Necozione S; Rea S
Anticancer Drugs; 2007 Jun; 18(5):597-604. PubMed ID: 17414629
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract][Full Text] [Related]
16. Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Recchia F; Candeloro G; Necozione S; Accorsi P; Recchia CO; Tombolini V; Rea S
Anticancer Res; 2010 Jan; 30(1):209-15. PubMed ID: 20150637
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Recchia F; Candeloro G; Rosselli M; Bratta M; Pasta V; D'Orazi V; Fumagalli LA; Rea S
Anticancer Res; 2015 Dec; 35(12):6847-53. PubMed ID: 26637906
[TBL] [Abstract][Full Text] [Related]
18. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ
Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
Recchia F; Candeloro G; Necozione S; Fumagalli L; Bratta M; Rea S
Anticancer Drugs; 2008 Feb; 19(2):201-7. PubMed ID: 18176117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
